STAT

HHS nominee Azar signals new line of attack on drug prices

Lawmakers are grilling Azar about his plans to bring down drug prices and his role in pricing decisions in his last job.
Alex Azar testifies during a Senate Finance Committee hearing on Tuesday. Source: Carolyn Kaster/AP

WASHINGTON — Alex Azar, Trump’s pick to lead the Health and Human Services Department, doubled down on his commitment to bringing down prescription drug prices Tuesday — and even added a new target for future policymaking: drug makers’ list prices.

Lawmakers at Azar’s confirmation hearing Tuesday before the Senate Finance Committee, like those at an earlier hearing before a separate panel, grilled him repeatedly about his plans, as president of Eli Lilly’s U.S. business.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Opinion: ICER’s Concern For Patients: Where’s The Beef?
ICER describes itself as the "nation's drug pricing watchdog." If it truly wants to be that, it needs to include the people who use health care in its assessments.
STAT4 min read
Opinion: Time In Range: A New Way For People With Diabetes To Monitor Blood Sugar
We've come a long way in the ability to measure blood sugar, from boiling urine with Benedict's solution to effort-free checks every few minutes with a continuous glucose monitor.
STAT3 min read
Not Only Who But What: NIH Funding Disparity Between Black And White Scientists Partly Driven By Research Topic
Not only who but what: NIH funding disparity between black and white scientists partly driven by research topic.